Last updated: April 24, 2026
Who manufactures or supplies Probenecid APIs and finished tablets?
Probenecid is a mature, generic small-molecule drug. In practice, “suppliers” split into two purchasing routes: (1) API manufacturers and (2) finished-dose manufacturers (tablets) that supply distributors and tenders. The supplier base changes materially by region (US/EU/ROW) and by whether you source via API trading or direct finished-dose procurement.
What supplier categories should procurement treat as distinct?
- API supplier (probenecid bulk drug substance): supplies active pharmaceutical ingredient for tablet manufacturing or compounding by licensed manufacturers.
- Finished-dose supplier (probenecid tablets): supplies finished tablets for wholesalers, hospitals, and tender channels.
- Distributors/importers: do not manufacture; source and distribute finished product, or act as import agents for region-specific registrations.
How to map Probenecid sourcing to compliance reality
Probenecid is typically sourced through:
- GxP-qualified API supply chains (DMF/CEP-backed, with site-specific GMP audits)
- Market-registered finished products (national registrations, pharmacovigilance, and batch release controls)
For procurement decisions, supplier qualification typically hinges on:
- GMP status at the manufacturing site
- Regulatory package (DMF or CEP for API; dossier for finished product)
- Batch release testing (identity, assay, impurities, residual solvents where applicable)
What does the supplier pool look like by product form?
1) Finished-dose tablets (most common procurement path)
Most supply contracts in major markets route through finished-dose manufacturers or their local importers/distributors because hospitals and distributors buy tablets directly, not API.
2) API (bulk probenecid)
API purchasing is used by:
- Generic tablet manufacturers
- Contract manufacturers producing probenecid as part of portfolio builds
- Specialty pharma and compounding operations (where legal)
Which supplier types dominate in practice?
- Generic manufacturers with established tablet lines
- API producers for mature, non-patent-locked small molecules
- Regional distributors with import and warehousing capability
What procurement signals should identify the right supplier?
For probenecid, buyers should verify these objective items before committing:
- Dosage form: tablets (strength and excipient package)
- Supply continuity: lead time stability (rolling schedule rather than spot shipments)
- Quality documentation:
- API: DMF/CEP linkage where applicable, CoA, impurity profile
- Finished product: registration status, CoA per batch, stability data package
- GxP chain integrity: audit results and change control maturity
Key Takeaways
- Probenecid sourcing splits cleanly into API suppliers and finished-dose tablet suppliers; treat them as different procurement lanes with different qualification requirements.
- In most markets, finished-dose procurement dominates because distribution and tender channels buy tablets, not bulk drug substance.
- Supplier selection for probenecid should be driven by site-level GMP qualification, regulatory dossier linkage (DMF/CEP where relevant), and batch release documentation, not by generic catalog availability.
FAQs
1) What is the most common way buyers source probenecid?
Finished-dose probenecid tablets through market-registered manufacturers and regional distributors.
2) When do buyers switch from finished tablets to API sourcing?
When they need cost-optimized custom manufacturing, contract tablet production, or internal formulation capabilities.
3) What documents matter most for API probenecid?
DMF or CEP linkage (where applicable), the site GMP evidence, and batch CoAs with impurity and identity/assay data.
4) Are supplier names stable for mature generics like probenecid?
Sites and listings remain, but availability and ranking shift by region, regulatory status, and batch scheduling.
5) What typically blocks a new probenecid supplier?
Site GMP qualification outcomes, missing or non-matching regulatory dossier elements, and inability to support consistent batch release specs.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). Drug approvals and databases (including Orange Book where applicable). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). European public assessment reports and medicines database. https://www.ema.europa.eu/
[3] World Health Organization. (n.d.). WHO prequalification of medicines programme. https://extranet.who.int/prequal/
